Dofamine

Quick links to important sections

Dofamine

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dofamine

Overview of Dofamine

Dofamine is a pharmacological agent primarily utilized in clinical settings to support cardiovascular function and address specific hemodynamic imbalances. It belongs to a class of medications known as inotropic agents, which influence the force of muscular contractions, particularly within the heart.

Mechanism of Action

The therapeutic effects of Dofamine are achieved through its interaction with specific receptors in the body, including dopaminergic, alpha-adrenergic, and beta-adrenergic receptors. The physiological response is often dose-dependent:

  • Low-Dose Range: Primarily targets dopaminergic receptors, which may assist in maintaining blood flow to vital organs such as the kidneys and intestines.
  • Moderate-Dose Range: Stimulates beta-1 adrenergic receptors, increasing the contractility of the heart muscle and improving cardiac output.
  • High-Dose Range: Activates alpha-adrenergic receptors, leading to vasoconstriction and an increase in systemic blood pressure.

Clinical Applications

Dofamine is typically indicated for patients experiencing acute states of low blood pressure or poor cardiac output. This includes conditions where the heart is unable to pump sufficient blood to meet the body's metabolic demands or during certain types of circulatory failure.

Because of its potent effects on heart rate and blood pressure, Dofamine is administered in controlled medical environments where continuous monitoring of vital signs can be maintained. It is delivered intravenously to allow for precise titration based on the patient's immediate physiological needs.

Regulatory References

  1. [(NIH: MedlinePlus)]
  2. U.S. National Library of Medicine
  3. National Institutes of Health
  4. [(PubChem)]

What side effects are possible with Dofamine?

Possible side effects and safety information

Dofamine (Dopamine hydrochloride) is associated with an official safety profile that centers primarily on cardiovascular and local vascular effects, as documented in regulatory prescribing information.

Adverse Reaction Classifications

Adverse reactions are officially categorized by frequency and the physiological system affected. Common effects, reported in official labels, include changes in heart rhythm such as tachycardia (rapid heart rate) or bradycardia (slow heart rate), palpitations, anginal pain, headache, and shifts in blood pressure (either hypertension or hypotension). Gastrointestinal disorders such as nausea and vomiting are also listed as common. Less frequent, or uncommon, reactions include piloerection (goosebumps) and specific ECG abnormalities.


Serious Safety Risks

The most serious documented safety concerns relate to the vascular system and heart function. These include the potential for ventricular arrhythmias and severe peripheral and visceral vasoconstriction (narrowing of blood vessels in the extremities and organs), which can lead to tissue ischemia. At the site of infusion, local necrosis, sloughing, and gangrene of the extremities have been reported, often associated with extravasation or prolonged, high-dose use. Furthermore, Dofamine contains the excipient sodium metabisulfite, which carries a risk of severe allergic-type reactions in susceptible individuals.


Safety Constraints and Special Populations

Regulatory documents stipulate that Dofamine is contraindicated in patients with pheochromocytoma (a tumor of the adrenal gland) or uncorrected tachyarrhythmias. A key safety constraint mandates that low blood volume (hypovolemia) must be corrected before administration to prevent severe vasoconstriction. Concerning specific groups, the safety and effectiveness in pediatric patients have not been established, and official notes exist regarding the potential for marked hypotension following the abrupt discontinuation of the infusion.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below summarizes the officially documented manifestations and required emergency actions for Dofamine (dopamine hydrochloride) overdosage, as detailed in governmental regulatory sources.

Documented Overdose Manifestations

Overdosage is primarily evidenced by the uncontrolled exaggeration of the drug's effects. Officially documented signs include a severe excessive elevation of blood pressure (hypertension) and cardiac disturbances, such as tachyarrhythmias or the development of new dysrhythmias.

Severe Outcomes and Risks

Severe complications documented in official labeling include rare instances of fatal ventricular arrhythmias. A key risk is tissue necrosis and sloughing due to local vasoconstriction if the infusion leaks out of the vein (extravasation). Gangrene of the extremities has also been reported following prolonged or high-dose infusions.

Required Emergency Actions

The immediate action for systemic overdosage, indicated by excessive blood pressure, is to reduce or temporarily discontinue the infusion. This action is rapidly effective due to the drug's short duration of action. For local tissue injury from extravasation, the official procedure requires the immediate infiltration of an alpha-adrenergic blocking agent (such as phentolamine mesylate) into the affected area to prevent tissue death.

Monitoring and Special Considerations

Constant monitoring is required, with attention to signs like a diminution of established urine flow rate or increasing tachycardia. Close monitoring is also advised for patients with impaired renal and hepatic function, as drug clearance may be decreased.

Therapeutic Uses of Dofamine

Quick Facts

  • Support for Hemodynamic Balance: Utilized in acute care settings to help address poor blood flow and low blood pressure.
  • Cardiac Support: May be used to support management of low cardiac output.
  • Organ Perfusion: Is administered to support the maintenance of adequate blood flow to vital organs, such as the kidneys.

What Dofamine treats: main uses and benefits

Dofamine is a compound administered in specific medical settings to help address hemodynamic imbalances, which relate to the flow of blood through the organs and tissues. It is indicated for the supportive management of certain forms of shock, including those related to heart attack (myocardial infarction), trauma, and septicemia. It is a treatment option used to help maintain blood pressure when it is considered too low (hypotension).

The compound may be used to support blood flow to vital organs, which can be affected by various acute conditions, such as open-heart surgery or kidney failure. By influencing the heart's function and the tension in blood vessels, Dofamine is intended to help restore a more balanced circulatory state. As a therapeutic agent, its use is generally reserved for patients in critical care who require careful medical monitoring and support.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility and Contraindications

Official regulatory documentation defines specific population groups who can and cannot use Dofamine (Dopamine hydrochloride injection).

Absolute Prohibitions

Dofamine is contraindicated and must not be used in the following populations:

  • Patients diagnosed with pheochromocytoma.
  • Individuals with uncorrected tachyarrhythmias or ventricular fibrillation.
  • Patients with a known hypersensitivity to the active substance or its excipients.

Restricted or Conditional Use

Administration is subject to specific conditions or requires caution in several populations:

  • Pediatric Patients: The safety and effectiveness of Dofamine have not been established in this age group, according to the official label.
  • Pregnancy: The drug is classified as Pregnancy Category C. Use is only warranted when the potential benefit outweighs the potential risk to the fetus.
  • Physiological State: Before and during use, underlying conditions such as hypovolemia, acidosis, and hypoxia must be identified and corrected.
  • Prior Medication Use: Patients who have recently used an MAO inhibitor (within two to three weeks) require a substantial reduction in the initial dosage.

Regulatory agencies primarily establish use for the adult population experiencing shock syndromes.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Dofamine (Dopamine hydrochloride) is strictly defined by regulatory authorities based on documented pharmacokinetic and pharmacodynamic effects with specific drug classes and substances.

Mandatory Restrictions and Prohibitions

Co-administration with Halogenated Hydrocarbon Anesthetics (such as Cyclopropane) is officially restricted because these agents may sensitize the myocardium, which carries a documented risk of severe ventricular arrhythmias and hypertension. Dofamine must also not be mixed with alkaline solutions (like Sodium Bicarbonate), as the drug is inactivated in these preparations.

Pharmacodynamic and Metabolic Interactions

  • Monoamine Oxidase Inhibitors (MAOIs): These agents significantly prolong and potentiate the effect of Dofamine due to the inhibition of its metabolic clearance. Regulatory guidelines require a mandatory dose adjustment if MAOIs were administered within two to three weeks prior to Dofamine.
  • Tricyclic Antidepressants (TCAs) and other Vasopressors (e.g., Oxytocin) may lead to severe persistent hypertension due to the additive potentiation of the drug's pressor response.
  • Alpha- and Beta-adrenergic Blocking Agents are documented to antagonize Dofamine’s effects on peripheral vasoconstriction and cardiac function, respectively.
  • Haloperidol and related drugs officially suppress the dopaminergic vasodilation documented at lower infusion rates.

Mechanism of Action

How Dofamine Works: Mechanism of Action

Dofamine (Dopamine hydrochloride) is a synthetic agent that exerts its effect through the concentration-dependent agonism of multiple peripheral receptor systems. Its mechanism involves sequentially engaging dopaminergic and adrenergic pathways to achieve a balanced cardiovascular response.

Modulation of Myocardial Contractility (beta1 Agonism)

This mechanism covers the direct stimulation of beta1-adrenergic receptors on myocardial cells. Activation increases intracellular cAMP and calcium levels. The resulting rise in cAMP promotes the influx of calcium ions ( Ca^2+), which increases the force of each heart muscle contraction. This action produces a positive inotropic effect, increasing the volume of blood ejected with each beat (stroke volume).

Sequential Vascular Tone Modulation ( D1 and alpha1 Agonism)

At lower concentrations, Dofamine acts on D1 receptors in the renal and mesenteric arteries, causing smooth muscle relaxation, which results in localized vasodilation and increased blood flow to these vascular beds. At higher concentrations, it targets alpha1 receptors to trigger widespread vasoconstriction, resulting in increased systemic vascular resistance. This domain provides dynamic control over peripheral resistance and blood flow.

Dosage and Administration Information

How to Use Dofamine

Dofamine (Dopamine Hydrochloride Injection) is strictly administered as a high-level medical procedure via continuous intravenous infusion. Due to the need for precise control and monitoring, the medication is reserved for use in a controlled critical care setting, such as an Intensive Care Unit. Administration requires the solution to be infused into a large vein using a specialized infusion pump to regulate the flow rate.

Preparation and Solution Rules

The sterile concentrate must be diluted prior to administration with approved solutions, which include 0.9% Sodium Chloride Injection or 5% Dextrose Injection. A key procedural instruction is to not mix Dofamine with alkaline substances, such as sodium bicarbonate, as this causes inactivation of the drug.

Official Dosing Protocol

The labeled dosage protocol requires the infusion to begin at a low initial rate for both adults and pediatric patients, typically ranging from 2 to 5 mcg/kg/minute. The dose is then subject to continuous titration (adjustment) in small increments, often 5 to 10 mcg/kg/minute, to maintain the desired physiological response. The official documents specify a maximum rate of 50 mcg/kg/minute that should not be exceeded.

Procedural and Population Adjustments

Underlying conditions, specifically hypovolemia and hypoxia, must be corrected before the Dofamine infusion is initiated. A specific rule exists for patients taking MAO inhibitors: the starting dose must be significantly reduced to one-tenth (1/10) of the usual rate. When the therapy is complete, the infusion rate must be gradually reduced (tapered) before full discontinuation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dofamine

Dofamine (Dopamine hydrochloride) was studied for research examining acute circulatory parameters in critical medical situations. The body of research primarily consists of Randomized Controlled Trials (RCTs) and systematic reviews conducted in acute care settings, evaluating it against vasopressor medicines. This evidence contributes to understanding symptom patterns observed so far in specific patient groups experiencing severe instability.


Evidence from Studies in Shock Syndrome

The most intensive research for Dofamine was evaluated in patients with circulatory shock (such as septic shock related to infection and cardiogenic shock associated with heart conditions). Research was studied for its impact on vital outcomes monitoring physiological strain or stress.

Study Focus: Survival and Mortality Outcomes

Studies monitored outcomes related to overall survival (typically tracked at 28 days post-treatment) and outcomes at hospital discharge. Trials evaluated Dofamine against other vasopressor agents, and data show patterns related to survival and hemodynamic parameters.

Data related to overall 28-day mortality evidence quality varies across studies and across different meta-analyses and large RCTs. Research highlights that when Dofamine was evaluated alongside other vasopressor agents, the studies reported that Dofamine was associated with the observation of cardiac arrhythmias (irregular heartbeats) in the observed populations. Furthermore, one major analysis of the data was associated with an observation of patterns related to survival in the specific subgroup of patients with cardiogenic shock when evaluated against a different vasopressor in the same trial.


Evidence for Hemodynamic Support and Organ Perfusion

Study Focus: Acute Physiological Responses

Dofamine was the subject of research focused on acute hemodynamic parameters in conditions marked by systemic or functional imbalance, such as hypotension (low blood pressure) and conditions associated with acute or disruptive episodes. These studies research examined key hemodynamic parameters in patients administered Dofamine, such as Mean Arterial Pressure and Cardiac Output.


What Remains Uncertain about Dofamine Research

The broader evidence landscape for Dofamine highlights several areas where certainty remains low or where additional research is needed:

  • Comparative evidence is lacking for many specific clinical scenarios when evaluating Dofamine against modern, alternative treatments.
  • The documented observation that Dofamine was associated with the observation of cardiac arrhythmias in comparative trials means that subgroup findings are uncertain.

Frequently Asked Questions (FAQ)

Common questions about Dofamine (FAQ)


Q: What is the difference between the generic and brand name Dofamine?

A: The official product information focuses on the active substance, dopamine hydrochloride. This active ingredient is consistent, as defined by regulatory documents, regardless of whether the specific product is labeled as a brand or a generic version. Regulatory documents define the drug based on this active substance.


Q: Does Dofamine contain any active ingredients other than the main drug substance?

A: Dofamine is defined as a single-ingredient product, containing only dopamine hydrochloride as the active medicine. However, the solution does contain other inactive substances, called excipients, such as sodium metabisulfite. Safety information includes a warning about this excipient, noting a potential for allergic-type reactions in susceptible individuals.


Q: If Dofamine is working, what general changes should someone expect to notice?

A: Dofamine is used in a critical care setting, where its effects are continuously monitored by medical staff. Official documents indicate that physiological responses associated with the drug's use can include observed changes such as increased urine flow, loss of pallor, and an increase in toe temperature. These signs are generally interpreted as indications of improved blood flow to vital organs.


Q: Is Dofamine something that requires long-term use?

A: Official prescribing information indicates Dofamine is intended for immediate circulatory support during acute, critical medical situations like shock. Its use is therefore defined for stabilization in these short-term, critical care settings, and it is administered as a continuous intravenous infusion.


Q: Are there any specific foods or beverages that should be described as interacting with Dofamine?

A: Regulatory documents provide detailed interaction profiles listing other medicines and alkaline solutions that should not be mixed with Dofamine. Official prescribing information does not list specific food or common beverage interactions that affect the medicine’s use.


Q: Are there different safety classifications for Dofamine use during pregnancy or breastfeeding?

A: For pregnancy, Dofamine is classified as Pregnancy Category C, meaning official guidance indicates use only when the potential benefit is considered to outweigh the potential risk to the fetus. For breastfeeding, official documents state that no information is available regarding its presence in human milk or its effects on the breastfed infant.


Q: Do the official documents mention any potential for dependency or withdrawal with Dofamine?

A: Regulatory documents do not mention the potential for dependency with Dofamine. However, official guidance strictly mandates a protocol for discontinuation, requiring the infusion rate to be gradually reduced (tapered). Official guidance warns that abrupt cessation is associated with marked hypotension (low blood pressure).


Q: What should be done if an expired package of Dofamine is found?

A: The medicine is supplied as a sterile solution for single use only. Official guidance states that any unused portion of the product and waste material must be immediately discarded. Disposal is required to follow local regulatory requirements, and official rules explicitly prohibit emptying the solution into drains or wastewater.


Q: Does taking Dofamine at the same time every day matter?

A: Dofamine is administered as a continuous intravenous infusion in a hospital setting, not as a scheduled dose taken at home. The infusion rate is continuously adjusted (titrated) by medical staff based on the patient's immediate physiological needs, so the concept of taking it at the 'same time every day' does not apply.


Q: Are there any restrictions on driving or operating machinery while using Dofamine?

A: Dofamine is required to be administered strictly by continuous intravenous infusion within a controlled critical care environment, such as an Intensive Care Unit. Because of the patient's medical condition and the setting of its use, the ability to drive or operate machinery during therapy is not applicable.


Q: Does the medicine come in more than one form (e.g., tablet, liquid, injection)?

A: The official pharmaceutical form of Dofamine is exclusively a sterile solution or a concentrate for solution for infusion. This means the medicine is prepared only for intravenous administration and is not available in oral forms like tablets, capsules, or any other form.

How should Dofamine be stored and disposed of?

Dofamine (Dopamine Hydrochloride) storage and disposal are strictly governed by regulatory requirements to ensure its stability and prevent environmental contamination.

Official Storage Conditions

Requirement Classification Constraint
Temperature Controlled Room Temperature Store at 20 C to 25 C (68 F to 77 F). Do not freeze.
Light Protection Mandatory Keep in the original outer carton to protect from light.
Integrity Visual Check Do not use if the solution is discolored (darker than slightly yellow) or contains particulate matter.
Child Safety Mandatory Keep out of the sight and reach of children.

Handling and Disposal

The medicine is supplied for single use only. The unused portion of the solution remaining in the vial or ampoule must be immediately discarded.

  • Stability: The diluted solution is typically stable for 24 hours at temperatures not exceeding 25 C.
  • Disposal Rule: All unused medicinal product and waste material must be disposed of in accordance with local requirements. Official guidelines prohibit emptying the solution into drains or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dofamine found in:

A-Z Index: